Position in EYPT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$36,414,250
New position
Shares Held
2,825,000
first reported quarter
Ownership
3.37%
of shares outstanding
% of Portfolio
2.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Commodore Capital LP holds $1,469,900,983 across 32 Biotechnology names. EYPT ranks #16 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLAY |
Relay Therapeutics, Inc.
|
17,000,000 | $169,150,000 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
3,275,000 | $128,380,000 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
2,888,007 | $111,159,389 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
1,912,380 | $96,460,447 | |
| 5 | TYRA |
Tyra Biosciences, Inc.
|
2,475,000 | $94,792,500 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
2,696,616 | $85,536,659 | |
| 7 | NUVL |
Nuvalent, Inc.
|
833,600 | $85,402,320 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
750,000 | $62,467,500 |
All Filings in EYPT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-05-27 | $55,930,000 | 4,250,000 | Shares | Sole | 2026-06-03 | |
| 2026-03-31 | $36,414,250 | 2,825,000 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||